Study of Pomaglumetad and Methamphetamine

Inclusion Criteria: 1. not seeking treatment for MA problems at the time of the study; 2. English-speaking; 3. age 18-55 years inclusive; 4. meet DSM-5 criteria for MA use disorder, moderate-severe as diagnosed via MINI; 5. have a self-reported history of using MA either via injection or smoking and provide at least one MA-positive urine prior to admission; 6. provide a urine drug screen negative for all illicit drugs, excepting THC, on the day of scheduled inpatient admission; 7. report methamphetamine use on 10 or more days in the past 30 days at baseline; 8. have a resting heart rate ≤ 100 bpm, systolic blood pressure ≤ 160 mm Hg, and diastolic blood pressure ≤ 100 mm Hg prior to admission; 9. have a baseline EKG that demonstrates normal sinus rhythm, QTc ≤ 450 msec in men or QTc ≤ 460 msec in women, and no clinically significant arrhythmias; 10. if female (except females of non-childbearing potential-e.g., at least 1 year post-menopausal or surgically sterile), not pregnant confirmed by negative pregnancy test nor lactating and willing to use a medically approved method of birth control to prevent pregnancy during the trial and for 40 days after the last dose of study medication; 11. if male, willing to refrain from donating sperm during the study and for 100 days following the last dose of study medication and agree that they and their partners will use a medically approved contraceptive method; 12. have a medical history and physical/neurological examination demonstrating no additional clinically significant contraindications for study participation, in the judgment of the investigators; 13. able to participate in all scheduled evaluations, likely to complete all scheduled tests, and likely to be adherent, in the opinion of the investigator and; 14. agree not to post any personal medical data or information related to the study on any social media site or website until the trial has completed. Exclusion Criteria: 1. non-English speaking; 2. currently on probation or parole; 3. have current cocaine, opioid, marijuana, or alcohol use disorder, moderate-severe; 4. have liver function tests (total bilirubin, ALT, AST, or alkaline phosphatase) ≥ 2 x the upper limit of normal or kidney function tests (creatinine and BUN) ≥ 2 x the upper limit of normal; 5. current or past history of seizure disorder; 6. a history of head trauma that resulted in neurological sequelae; 7. major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar illness but excepting stable major depressive disorder, generalized anxiety disorder, etc.) as assessed by the MINI; 8. have a current neurological disorder (e.g., organic brain disease, dementia) or medical condition which would make study compliance difficult or compromise informed consent; 9. current ongoing treatment with psychotropic medications (e.g. antidepressants, antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics); 10. history of suicide attempt(s) in the past 6 months or active suicidal intention or plan (score 4 or 5) in the past month as assessed by the C-SSRS; 11. evidence of clinically significant heart disease or hypertension; 12. evidence of untreated or unstable serious medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease including active tuberculosis infection; 13. have HIV infection and currently symptomatic, have a diagnosis of AIDS, or are receiving antiretroviral medication; 14. have a medical condition that makes maintaining reliable intravenous access impossible; 15. donated blood or plasma within 3 months of inpatient admission; 16. use of OAT1 inhibitor (e.g. probenecid, uricosurics, antivirals, nonsteroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, proton pump inhibitors, or statins) or CYP2D6 inducers or inhibitors within 14 days or five half-lives, whichever is longer, from admission; 17. currently employed by UCLA or Denovo or a first-degree relative of UCLA or Denovo employee or; 18. any other circumstances that, in the opinion of the investigators, would compromise participant safety and/or successful completion of the trial.